Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Clinical Impact of Systematic Screening for Obstructive Sleep Apnea in a Type 2 Diabetes Population-Adherence to the Screening-Diagnostic Process and the Acceptance and Adherence to the CPAP Therapy Compared to Regular Sleep Clinic Patients

K. Westlake, V. Dostalova, A. Plihalova, M. Pretl, J. Polak,

. 2018 ; 9 (-) : 714. [pub] 20181129

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001433

Grantová podpora
NV15-30155A MZ0 CEP - Centrální evidence projektů

Obstructive sleep apnea (OSA) is a common disorder in Type 2 diabetes (T2D) patients further increasing their already high cardiovascular risk. As T2D patients typically not report OSA symptoms, systematic screening for OSA in this population is warranted. We aimed to determine the readiness of T2D patients to undergo screening and to compare their adherence to continuous positive airway pressure (CPAP) therapy with "regular" sleep clinic patients who typically seek medical advice on their own initiative. We therefore recruited 494 consecutive T2D patients and offered them OSA screening using home sleep monitoring (type IV device). All participants in high risk of moderate-to-severe OSA were recommended home sleep apnea testing (HSAT) followed by CPAP therapy. Patients were followed-up for 12 months and outcomes compared to 228 consecutive sleep clinic patients undergoing HSAT. Among 307 screened T2D patients, 94 (31%) were identified at high risk of moderate-to-severe OSA. Subsequently, 54 patients underwent HSAT, 51 were recommended, and 38 patients initiated CPAP (acceptance 75%). Among 228 sleep clinic patients, 92 (40%) were recommended and 74 patients initiated CPAP (acceptance 80%). After 1 year, 15 (39%) T2D and 29 (39%) sleep clinic patients showed good CPAP adherence (use ≥ 4 h/night ≥ 70% nights). In conclusion, 20 T2D patients needed to be screened in order to obtain one successfully treated patient. OSA screening in T2D patients identified 31% with moderate-to-severe OSA. Once diagnosed, their CPAP acceptance and adherence did not differ from sleep clinic patients. However, the reasons for the high dropout during the screening-diagnostic process impacting the overall success of the screening program need to be identified and addressed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001433
003      
CZ-PrNML
005      
20240723092251.0
007      
ta
008      
190107e20181129sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2018.00714 $2 doi
035    __
$a (PubMed)30555416
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Westlake, Katerina $u Second Internal Medicine Department, Vinohrady Teaching Hospital, Prague, Czechia. Diabetology Practice Diabetologie Praha, Prague, Czechia. Department of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czechia.
245    14
$a The Clinical Impact of Systematic Screening for Obstructive Sleep Apnea in a Type 2 Diabetes Population-Adherence to the Screening-Diagnostic Process and the Acceptance and Adherence to the CPAP Therapy Compared to Regular Sleep Clinic Patients / $c K. Westlake, V. Dostalova, A. Plihalova, M. Pretl, J. Polak,
520    9_
$a Obstructive sleep apnea (OSA) is a common disorder in Type 2 diabetes (T2D) patients further increasing their already high cardiovascular risk. As T2D patients typically not report OSA symptoms, systematic screening for OSA in this population is warranted. We aimed to determine the readiness of T2D patients to undergo screening and to compare their adherence to continuous positive airway pressure (CPAP) therapy with "regular" sleep clinic patients who typically seek medical advice on their own initiative. We therefore recruited 494 consecutive T2D patients and offered them OSA screening using home sleep monitoring (type IV device). All participants in high risk of moderate-to-severe OSA were recommended home sleep apnea testing (HSAT) followed by CPAP therapy. Patients were followed-up for 12 months and outcomes compared to 228 consecutive sleep clinic patients undergoing HSAT. Among 307 screened T2D patients, 94 (31%) were identified at high risk of moderate-to-severe OSA. Subsequently, 54 patients underwent HSAT, 51 were recommended, and 38 patients initiated CPAP (acceptance 75%). Among 228 sleep clinic patients, 92 (40%) were recommended and 74 patients initiated CPAP (acceptance 80%). After 1 year, 15 (39%) T2D and 29 (39%) sleep clinic patients showed good CPAP adherence (use ≥ 4 h/night ≥ 70% nights). In conclusion, 20 T2D patients needed to be screened in order to obtain one successfully treated patient. OSA screening in T2D patients identified 31% with moderate-to-severe OSA. Once diagnosed, their CPAP acceptance and adherence did not differ from sleep clinic patients. However, the reasons for the high dropout during the screening-diagnostic process impacting the overall success of the screening program need to be identified and addressed.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dostálová, Veronika $u Neurology and Sleep Laboratory, INSPAMED Ltd., Prague, Czechia. Institute of Sleep Medicine, Prague, Czechia. Diamant Neuropsychology Laboratory, Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czechia. $7 xx0320210
700    1_
$a Plihalova, Andrea $u Second Internal Medicine Department, Vinohrady Teaching Hospital, Prague, Czechia. Department of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Pretl, Martin $u Neurology and Sleep Laboratory, INSPAMED Ltd., Prague, Czechia. Institute of Sleep Medicine, Prague, Czechia.
700    1_
$a Polak, Jan $u Second Internal Medicine Department, Vinohrady Teaching Hospital, Prague, Czechia. Department of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czechia.
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 9 (20181129), s. 714
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30555416 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20240723092248 $b ABA008
999    __
$a ind $b bmc $g 1365267 $s 1039556
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 714 $e 20181129 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
GRA    __
$a NV15-30155A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...